Wipfli Financial Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Wipfli Financial Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$13K	Buy	+1,342	New	+$14.2K	﹤0.01%	1761

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Wipfli Financial Advisors's VNDA Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Vanda Pharmaceuticals (VNDA) in Q3 2022: 1,342 shares worth $13K. The stake represents ﹤0.01% of the portfolio and ranks #1761 among its holdings.

178 funds tracked by Wall St. Rank hold VNDA as of Q3 2022.

Wipfli Financial Advisors held 1,342 shares of Vanda Pharmaceuticals worth $13K as of Q3 2022.
Vanda Pharmaceuticals was a new Wipfli Financial Advisors position in Q3 2022.
Vanda Pharmaceuticals made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1761 holding.
178 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.